Scott Kellen
2022
In 2022, Scott Kellen earned a total compensation of $563.6K as Chief Financial Officer and Secretary at DiaMedica Therapeutics, a 3% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $101,983 |
|---|---|
| Option Awards | $116,549 |
| Salary | $329,392 |
| Other | $15,650 |
| Total | $563,574 |
Kellen received $329.4K in salary, accounting for 58% of the total pay in 2022.
Kellen also received $102K in non-equity incentive plan, $116.5K in option awards and $15.7K in other compensation.
Rankings
In 2022, Scott Kellen's compensation ranked 4,158th out of 5,758 executives tracked by ExecPay. In other words, Kellen earned more than 27.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,158 out of 5,758 | 28th |
Division Manufacturing | 2,350 out of 3,135 | 25th |
Major group Chemicals And Allied Products | 1,143 out of 1,421 | 20th |
Industry group Drugs | 1,073 out of 1,322 | 19th |
Industry Pharmaceutical Preparations | 786 out of 968 | 19th |
Source: SEC filing on April 4, 2023.
Kellen's colleagues
We found two more compensation records of executives who worked with Scott Kellen at DiaMedica Therapeutics in 2022.
News
DiaMedica Therapeutics CEO Rick Pauls' 2023 pay rises 12% to $1.2M
April 4, 2024
DiaMedica Therapeutics CEO Rick Pauls' 2022 pay slips 5% to $1.1M
April 4, 2023
DiaMedica Therapeutics CEO Rick Pauls' 2021 pay jumps 29% to $1.1M
April 5, 2022
DiaMedica Therapeutics CEO Rick Pauls' 2019 pay jumps 105% to $1.5M
April 20, 2020
DiaMedica Therapeutics CEO Rick Pauls' 2018 pay jumps 46% to $734K
April 8, 2019